A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

skynesher/E+ via Getty Images After Esperion Therapeutics (NASDAQ:ESPR) rolled out a secondary offering in mid-January, the initial selling looked set to undermine an otherwise promising biotech story. Fortunately, ESPR never looked back from its gap down open and in turn the stock set up a fresh buying opportunity. Roll the calendar forward to the company’s recent earnings report, and I can release my next sigh of relief. The post-earnings gain of 10.3% was not enough for a breakout, but momentum at le ...